Reflections on the Collaborative Fight Against COVID-19

Area of Science:

• Infectious Diseases
• Clinical Trial Design
• Patient-Centered Research

Background:

• Numerous clinical trials are underway globally to find effective COVID-19 treatments.
• Historically, patient perspectives have been underrepresented in the design of these trials.
• Emerging interest in early-phase COVID-19 therapeutic interventions necessitates a shift in trial methodology.

Purpose of the Study:

• To advocate for the inclusion of patient organizations in the design of clinical protocols for COVID-19 treatments.
• To emphasize the importance of patient input in defining relevant clinical trial endpoints.
• To highlight the need for patient involvement in assessing the risk-benefit balance of novel therapies.

Main Methods:

• This study presents a perspective and argument for patient involvement.
• It reviews the current landscape of COVID-19 clinical trials.
• It proposes a framework for integrating patient organizations into trial design.

Main Results:

• Current clinical trial designs for COVID-19 treatments often overlook patient priorities.
• Integrating patient organizations can lead to more meaningful and relevant trial outcomes.
• Patient input is essential for a comprehensive risk-benefit assessment.

Conclusions:

• Patient organizations should be integral to the design of COVID-19 clinical trials.
• Involving patients ensures that trial endpoints and risk-benefit assessments align with patient values.
• This collaborative approach will enhance the relevance and efficiency of therapeutic development for COVID-19.